View Future GrowthVimab Group 과거 순이익 실적과거 기준 점검 0/6Vimab Group 의 수입은 연평균 -46.2%의 비율로 감소해 온 반면, Professional Services 산업은 연평균 10.2%의 비율로 증가했습니다. 매출은 연평균 4.6%의 비율로 증가해 왔습니다.핵심 정보-46.21%순이익 성장률13.07%주당순이익(EPS) 성장률Professional Services 산업 성장률14.49%매출 성장률4.64%자기자본이익률-651.31%순이익률-27.89%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.모든 업데이트 보기Recent updatesNew Risk • Jun 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 81% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr56m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€12.3m market cap, or US$14.3m).Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Gunnar Jardelöv was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 13Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026, at 10:00 W. Europe Standard Time. Location: wigge & partners law kb`s premises, at birger jarlsgatan 25 in, stockholm Sweden공시 • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights Offering공시 • May 14Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm Sweden공시 • Dec 21An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million.An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB.New Risk • Nov 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (35% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€22.2m market cap, or US$24.2m).Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).New Risk • Jun 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr886k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr886k free cash flow). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (€18.9m market cap, or US$20.2m).Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).공시 • May 08Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm SwedenNew Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€18.4m market cap, or US$20.1m).Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€17.4m market cap, or US$18.4m).매출 및 비용 세부 내역Vimab Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:NM4 매출, 비용 및 순이익 (SEK Millions)날짜매출순이익일반관리비연구개발비31 Mar 26332-9381031 Dec 25318-10280030 Sep 25315-9186030 Jun 25297-9788031 Mar 25313-9094031 Dec 24325-7797030 Sep 24353-3994030 Jun 24376-2397031 Mar 24370-1289031 Dec 23342-484030 Sep 23295-1477030 Jun 23255-2663031 Mar 23237-2761031 Dec 22227-3457030 Sep 22211-2855031 Dec 21206-2456031 Dec 20217-46450양질의 수익: NM4 은(는) 현재 수익성이 없습니다.이익 마진 증가: NM4는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: NM4은 수익성이 없으며 지난 5년 동안 손실이 연평균 46.2% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 NM4의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: NM4은 수익성이 없어 지난 해 수익 성장률을 Professional Services 업계(4%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: NM4는 현재 수익성이 없으므로 자본 수익률이 음수(-651.31%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YCommercial-services 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/07 02:58종가2026/06/05 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vimab Group AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).
Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).
Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.
New Risk • Jun 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 81% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr56m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 46% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€12.3m market cap, or US$14.3m).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman of the Board Gunnar Jardelöv was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 13Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026Vimab Group AB (publ), Annual General Meeting, Jun 09, 2026, at 10:00 W. Europe Standard Time. Location: wigge & partners law kb`s premises, at birger jarlsgatan 25 in, stockholm Sweden
공시 • Dec 03Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million.Vimab Group AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 127.416758 million. Security Name: Shares Security Type: Common Stock Securities Offered: 26,545,158 Price\Range: SEK 4.8 Transaction Features: Rights Offering
공시 • May 14Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025Vimab Group AB (publ), Annual General Meeting, Jun 10, 2025, at 10:00 W. Europe Standard Time. Location: at wigge & partners advokat kb`s premises, at birger jarlsgatan 25, stockholm Sweden
공시 • Dec 21An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million.An undisclosed buyer signed a letter of intent to acquire Vimab Ab from Vimab Group AB (publ) (OM:VIMAB) for SEK 200 million on December 19, 2024. The divestment is intended to take place for a purchase price of approximately SEK 200 million on a cash and debt-free basis, which will be paid in cash when the shares are acquired. Net sales for Vimab AB in the financial year 2023 amounted to approximately SEK 200.1 million with an EBITDA result of approximately SEK 23.1 million, which corresponds to an EBITDA margin of approximately 11.5 percent. The divestiture is conditional on the Stakeholder's due diligence and the parties agreeing to enter into a share transfer agreement. Signing of the share transfer agreement and access is planned for the first quarter of 2025. Mangold Fondkommission AB acted as financial advisor for Vimab Group AB. Wigge & Partners Advokat Kb acted as legal advisor for Vimab Group AB.
New Risk • Nov 05New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr5.8m free cash flow). Share price has been highly volatile over the past 3 months (35% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (€22.2m market cap, or US$24.2m).
Reported Earnings • Aug 25Second quarter 2024 earnings released: kr0.20 loss per share (vs kr0.36 profit in 2Q 2023)Second quarter 2024 results: kr0.20 loss per share (down from kr0.36 profit in 2Q 2023). Revenue: kr96.7m (up 8.2% from 2Q 2023). Net loss: kr3.63m (down 150% from profit in 2Q 2023).
New Risk • Jun 16New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr886k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-kr886k free cash flow). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (€18.9m market cap, or US$20.2m).
Reported Earnings • May 09First quarter 2024 earnings released: kr0.80 loss per share (vs kr0.53 loss in 1Q 2023)First quarter 2024 results: kr0.80 loss per share (further deteriorated from kr0.53 loss in 1Q 2023). Revenue: kr68.5m (up 72% from 1Q 2023). Net loss: kr17.9m (loss widened 72% from 1Q 2023).
공시 • May 08Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024Vimab Group AB (publ), Annual General Meeting, Jun 04, 2024, at 10:00 W. Europe Standard Time. Location: wigge & partners advokat kb`s, premises at birger jarlsgatan 25, stockholm Sweden
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Market cap is less than US$100m (€18.4m market cap, or US$20.1m).
Reported Earnings • Mar 13Full year 2023 earnings released: kr0.30 loss per share (vs kr3.44 loss in FY 2022)Full year 2023 results: kr0.30 loss per share (improved from kr3.44 loss in FY 2022). Revenue: kr347.8m (up 53% from FY 2022). Net loss: kr4.26m (loss narrowed 88% from FY 2022).
Reported Earnings • Nov 15Third quarter 2023 earnings released: EPS: kr0.20 (vs kr0.49 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.20 (up from kr0.49 loss in 3Q 2022). Revenue: kr99.7m (up 69% from 3Q 2022). Net income: kr4.86m (up kr12.0m from 3Q 2022). Profit margin: 4.9% (up from net loss in 3Q 2022). The move to profitability was driven by higher revenue.
New Risk • Oct 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Market cap is less than US$100m (€17.4m market cap, or US$18.4m).